Evidence map›Paper›PMID 38806422›Full record

ArticleBMJ open2024

Smoking, nicotine and pregnancy 2 (SNAP2) trial: protocol for a randomised controlled trial of an intervention to improve adherence to nicotine replacement therapy during pregnancy.

Miranda M Clark, Sue Cooper, Felix Naughton, Michael Ussher, Joanne Emery, Lisa McDaid, Ross Thomson, Lucy Phillips, Linda Bauld, Paul Aveyard and 14 more

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Miranda M ClarkCentre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK miranda.clark@nottingham.ac.uk.ORCID 0000-0002-6179-046X
Sue CooperCentre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0002-1994-6395
Felix NaughtonAddiction Research Group, School of Health Sciences, University of East Anglia, Norwich, UK.ORCID 0000-0001-9790-2796
Michael UssherPopulation Health Research Institute, St George's University of London, London, UK.
Joanne EmeryAddiction Research Group, School of Health Sciences, University of East Anglia, Norwich, UK.
Lisa McDaidAddiction Research Group, School of Health Sciences, University of East Anglia, Norwich, UK.
Ross ThomsonCentre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.ORCID 0000-0003-4078-0657
Lucy PhillipsCentre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.
Linda BauldUsher Institute and Behavioural Research UK, The University of Edinburgh, Edinburgh, UK.ORCID 0000-0001-7411-4260
Paul AveyardNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.ORCID 0000-0002-1802-4217
David TorgersonYork Trials Unit, Department of Health Sciences, University of York, York, UK.
Ivan BerlinDepartment of Medical Pharmacology, Pitié Salpêtrière Hospital-Sorbonne Université, Paris, France.ORCID 0000-0002-5928-5616
Sarah LewisSchool of Medicine, University of Nottingham, Nottingham, UK.
Steve ParrottDepartment of Health Sciences, University of York, York, UK.
Catherine HewittYork Trials Unit, Department of Health Sciences, University of York, York, UK.
Charlie WelchYork Trials Unit, Department of Health Sciences, University of York, York, UK.
Gill ParkinsonYork Trials Unit, Department of Health Sciences, University of York, York, UK.
Anne DickinsonCentre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.
Stephen SuttonBehavioural Science Group, University of Cambridge, Cambridge, UK.ORCID 0000-0003-1610-0404
James BrimicombeCambridge Research Methods Hub, University of Cambridge, Cambridge, UK.
Katharine BowkerCentre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.
Andrew McEwenNational Centre for Smoking Cessation and Training (NCSCT), Dorchester, UK.
Kavita VedharaSchool of Psychology, Cardiff University, Cardiff, UK.ORCID 0000-0002-9940-7534
Tim ColemanCentre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSmoking during pregnancy is harmful to unborn babies, infants and women. Nicotine replacement therapy (NRT) is offered as the usual stop-smoking support in the UK. However, this is often used in insufficient doses, intermittently or for too short a time to be effective. This randomised controlled trial (RCT) explores whether a bespoke intervention, delivered in pregnancy, improves adherence to NRT and is effective and cost-effective for promoting smoking cessation. METHODS AND ANALYSIS: A two-arm parallel-group RCT was conducted for pregnant women aged ≥16 years and who smoke ≥1 daily cigarette (pre-pregnancy smoked ≥5) and who agree to use NRT in an attempt to quit. Recruitment is from antenatal care settings and via social media adverts. Participants are randomised using blocked randomisation with varying block sizes, stratified by gestational age (<14 or ≥14 weeks) to receive: (1) usual care (UC) for stop smoking support or (2) UC plus an intervention to increase adherence to NRT, called 'Baby, Me and NRT' (BMN), comprising adherence counselling, automated tailored text messages, a leaflet and website. The primary outcome is biochemically validated smoking abstinence at or around childbirth, measured from 36 weeks gestation. Secondary outcomes include NRT adherence, other smoking measures and birth outcomes. Questionnaires collect follow-up data augmented by medical record information. We anticipate quit rates of 10% and 16% in the control and intervention groups, respectively (risk ratio=1.6). By recruiting 1320 participants, the trial should have 90% power (alpha=5%) to detect this intervention effect. An economic analysis will use the Economics of Smoking in Pregnancy model to determine cost-effectiveness. ETHICS AND DISSEMINATION: Ethics approval was granted by Bloomsbury National Health Service's Research Ethics Committee (21/LO/0123). Written informed consent will be obtained from all participants. Findings will be disseminated to the public, funders, relevant practice/policy representatives, researchers and participants. TRIAL REGISTRATION NUMBER: ISRCTN16830506. PROTOCOL VERSION: 5.0, 10 Oct 2023.

Indexed as

Smoking CessationTobacco Use Cessation DevicesAdultCost-Benefit AnalysisCounselingFemaleHumansNicotine Replacement TherapyPregnancyPregnancy ComplicationsPrenatal CareRandomized Controlled Trials as TopicSmokingmaternal medicinepublic healthrespiratory medicine (see thoracic medicine)smoking reduction

Identifiers

PMID38806422
PMCPMC11138292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.